Hydroxychloroquine sulfate Indications And Usage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Hydroxychloroquine sulfate}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDROXYCHLOROQUINE SULFATE (...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Indications And Usage== | |||
Hydroxychloroquine sulfate tablets, USP are indicated for the suppressive treatment and treatment of acute attacks of malaria due to [[Plasmodium vivax]], P. malariae, P. ovale, and susceptible strains of P. falciparum. Hydroxychloroquine sulfate tablets, USP are also indicated for the treatment of discoid and systemic lupus erythematosus, and [[rheumatoid arthritis]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDROXYCHLOROQUINE SULFATE (HYDROXYCHLOROQUINE SULFATE) TABLET, FILM COATED [IPCA LABORATORIES LIMITED] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22d4d993-b86d-478e-ac6d-7bcd217e9906 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDROXYCHLOROQUINE SULFATE (HYDROXYCHLOROQUINE SULFATE) TABLET, FILM COATED [IPCA LABORATORIES LIMITED] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22d4d993-b86d-478e-ac6d-7bcd217e9906 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 23:57, 7 January 2014
| Hydroxychloroquine sulfate |
|---|
| HYDROXYCHLOROQUINE SULFATE® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications And Usage |
| Contraindications |
| Warnings And Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage And Administration |
| How Supplied |
| Labels And Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
Hydroxychloroquine sulfate tablets, USP are indicated for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. Hydroxychloroquine sulfate tablets, USP are also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.[1]
References
Adapted from the FDA Package Insert.